be associated with an increased risk of fatal hemorrhagic stroke 18 or intracranial bleeding. 21 An elevated risk of hemorrhagic stroke with the combined use of SSRI/SNRI and aspirin has been reported, 13 but earlier studies did not show any potentiating effect of SSRI/SNRI on the risk conferred by warfarin. 11 A recent epidemiological metaanalysis including over 500,000 patients has suggested that SSRIs/SNRIs increase the risk of ICH and that the risk of bleeding rises when oral anticoagulants are combined with SSRIs/SNRIs as compared with the risk when oral anticoagulants are used alone. 8 Since SSRIs/SNRIs may cause abnormal bleeding and their combination with warfarin may result in simultaneous impairment of both primary and secondary hemostasis, we hypothesized that the outcome in patients taking both warfarin and SSRI/SNRI simultaneously when suffering from ICH may be very poor. We investigated this hypothesis in a defined population for which we had accurate data on medication and the occurrence of warfarin-associated primary ICH (WA-PICH).
Methods
The ethics committee of the Northern Ostrobothnia Hospital District approved the protocol.
Patient Population
We conducted a population-based study for the period from January 1, 1993, through December 31, 2008. We identified 982 subjects with PICH among the population of Northern Ostrobothnia, Finland. Oulu University Hospital is the only hospital in the area serving patients with acute stroke (population 1993-2008: 356,026-389,671). We excluded patients not living in the hospital's catchment area as well as those who had brain tumor, aneurysm, vascular malformation, hematological malignancy, hemophilia, or head trauma. Six patients died before reaching the hospital and were identified from the Causes of Death Register (Statistics Finland), which collects the death certificates of all decedents in Finland. Autopsy reports included data on drugs used by the subjects at the time of death. All 6 of these patients had been using warfarin. Warfarin use at the time of PICH was required for study inclusion.
Neuroradiological Methods
Primary ICH was verified with a brain CT on admission in all cases. Experienced neuroradiologists analyzed all available CT scans and other imaging examinations and recorded the locations and measured the volumes of the hematomas. The methods used to measure hematoma volumes have been described elsewhere. 9 Digital subtraction angiography, CT, or MRI was performed immediately in 33 subjects to rule out aneurysms and arteriovenous malformations as the cause of hemorrhage. Survivors were checked for other structural abnormalities with follow-up brain imaging (CT or MRI) 2-3 months after the bleeding.
Clinical Data
Each patient's clinical condition on admission was assessed using the Glasgow Coma Scale (GCS). 19 Information about previous diseases, blood pressure history, and the prescription of anticoagulants or other medications was extracted from the hospital records. Patients were considered to be hypertensive either if their blood pressure readings before the index stroke had repeatedly exceeded 160/90 mm Hg, in accordance with the statement from the World Health Organization and International Society of Hypertension, 22 or if they were taking antihypertensive medication. The patients were recorded as having diabetes mellitus if they were taking oral hypoglycemic agents or insulin. Cardiac disease included myocardial infarction, coronary artery disease, heart failure, and/or atrial fibrillation.
Data on the use of drugs were obtained from the hospital records and double-checked on the national register of prescribed medicines kept by the Social Insurance Institution of Finland. Such data include all drug purchases by individuals linked to personal social security numbers. However, the use of aspirin is not registered because aspirin is available without prescription in Finland. We paid particular attention to anticoagulants, antiplatelet agents, SSRIs, and SNRIs.
Patient Management
Blood pressure management, thromboprophylaxis, and the reversal of warfarin treatment were accomplished according to the institution and hospital treatment protocols described earlier. 10, 14, 20 To prevent hematoma growth, patients who had been on warfarin were immediately given either fresh-frozen plasma or prothrombin complex concentrate (PTCC) together with vitamin K to restore coagulation factors and to lower the international normalized ratio (INR). This treatment was not given to patients who were moribund on admission. Surgical hematoma evacuation was performed in 20 patients.
Statistical Methods
Data were analyzed with SPSS for Windows (release 20.0.0, IBM). Categorical variables were compared using conventional statistical methods including Pearson's chi-square test, Fisher's exact test, t-tests, and/or 1-way ANOVA. For the life table analysis, each patient was followed up until death or until 1 month after PICH. The cumulative risk of death was estimated with the KaplanMeier product-limit method, and the curves for the various groups were compared using the log-rank test. Cox proportional-hazards regression analysis was performed to determine the hazard ratios and 95% confidence intervals of the variables that predicted 30-day case fatality. The following variables were included in the model: sex, age, cardiac disease, diabetes, hematoma size, GCS score, presence of intraventricular hematoma, INR on arrival, use of PTCC, hematoma evacuation, use of warfarin alone, use of warfarin combined with aspirin, and use of warfarin combined with an SSRI/SNRI. The proportionality assumption was checked. The test for significance was based on changes in log (partial) likelihood. A 2-tailed p value < 0.05 was considered to be statistically significant.
Results
Of the 176 patients with WA-PICH who were eligible for analysis, 140 (79.5%) had received warfarin medication alone, whereas 17 (9.6%) had had warfarin plus aspirin (ASA group) and 19 (10.8%) had received warfarin combined with SSRI/SNRI (SSRI/SNRI group). The se ro tonin-modulating antidepressants concerned were citalopram (6 patients), mirtazapine (5, an SNRI drug), escitalopram (5), paroxetine (2), and fluoxetine (1). Characteristics, treatments, and case fatalities are listed in Ta were observed among the groups on admission, nor were any significant differences observed in the frequency of medical (PTCC) or surgical (hematoma evacuation) treatments. The case fatality rate among the groups was not significantly different (p = 0.063). Primary ICH was an immediate cause of death in 12 (80%) of 15 patients in the SSRI/SNRI group, 10 (100%) of 10 in the ASA group, and 61 (86%) of 71 in the group with warfarin alone.
Survival among the subjects classified by warfarin treatment is graphically illustrated in Fig. 1 , where the 30-day case fatality rates were 50.7% for those receiving warfarin alone, 58.8% for the ASA group, and 78.9% for the SSRI/SNRI group (p = 0.033, warfarin plus SSRI/SNRI compared with warfarin alone). Three subjects (in the SSRI/SNRI group) had been taking both aspirin and an SSRI/SNRI together with warfarin. After excluding these 3 subjects from our analysis, we calculated an even greater difference in case fatality rates between the subjects receiving warfarin alone and those taking it with SSRI/ SNRI (87.5% vs 50.7%, p = 0.006).
Independent predictors for death were analyzed using Cox proportional-hazards regression analysis, which included all well-known variables affecting case fatality together with medication data. A low GCS score, large hematoma size, intraventricular hemorrhage, high INR on admission, and SSRI/SNRI together with warfarin were all significant predictors of 30-day case fatality in univariable analyses, whereas PTCC treatment showed a protective effect (Table 2) . In multivariable analyses, however, only a low GCS score, large hematoma size, and the combination of warfarin plus an SSRI/SNRI significantly and independently increased the risk of death within the first 30 days after bleeding (adjusted HR 2.10, 95% CI 1.13-3.92, p = 0.019).
The association with fatal bleeding was not equal among the 19 patients who had taken SSRI/SNRI together with warfarin. Three of the 5 patients receiving mirtazapine had demonstrated a small hematoma (≤ 10 ml) on admission, and one of them survived. The 3 patients receiving a high-affinity SSRI/SNRI (paroxetine or fluoxetine) had presented with large hematomas, and 2 died within a couple of days (70 and 100 ml) and the third died within 3 weeks after hematoma evacuation (63 ml). The case fatality rate was no lower among the 11 patients who had received an intermediate-affinity SSRI/SNRI (citalopram or escitalopram) together with the warfarin; the only patient who survived had had a small hematoma (2 ml) and was immediately treated with PTCC. Among the 10 patients who died, 2 had had hematomas evacuated (one a 28 ml cerebellar hematoma and the other a 69 ml subcortical hematoma), while the rest had presented with very large hematomas on admission and died within 3 days.
Discussion
Our major finding was the increased case fatality rate in patients who had been receiving warfarin together with SSRI/SNRI, an effect that was independent of confounding factors on admission. As expected, an impaired level of consciousness and a large hematoma volume on admission were significant predictors of case fatality. This paper is the first report of a higher case fatality rate after ICH among patients who had been on SSRIs/ SNRIs plus warfarin than that among patients who had been on warfarin alone. The reason for this is unclear, however. It has been postulated that some patients may have a high risk of major bleeding while taking an oral anticoagulant together with an SSRI/SNRI, 3 but whether genetic or other factors are responsible for the difference remains unclear. Since the frequencies of conventional risk factors for ICH were similar among all our patient groups, we assume that the hematomas in patients who had been receiving SSRI/SNRI were more frequently enlarged than those in the subjects who were on warfarin alone. We assume that the enlargement had taken place more rapidly, but this remains to be proved given that repeated head CT scans were seldom available. Nonetheless, the most common immediate cause of death was the direct effect of ICH in all warfarin groups (80%-100%).
Interestingly, the combination of warfarin and SSRI/ SNRI may be associated with greater case fatality than the combination of warfarin and aspirin. Warfarin inhibits the hepatic synthesis of vitamin K-dependent clotting factors, while aspirin irreversibly inactivates platelet cyclooxygenase, preventing the synthesis of thromboxane A 2 , resulting in impaired platelet secretion and aggregation. Aspirin also displaces warfarin that is bound to albumin and could thereby lead to an enhanced effect of warfarin, as suggested by the fact that the combined use of aspirin with warfarin has entailed an increased risk of bleeding.
5,7
Both aspirin and SSRI/SNRI affect primary hemostasis, but through different mechanisms. SSRI/SNRI re duces the platelet serotonin content and impairs both platelet secretory response and platelet aggregation. 3 The effect on hemostasis may be mediated by other, more direct mechanisms, however, such as interaction with the glycoprotein IIb/IIIa receptor. 6 In a previous case-control study, the combination of SSRI/SNRI and aspirin did not entail a significantly greater risk of hemorrhagic stroke than did aspirin alone, 11 whereas a population-based retrospective cohort study indicated that the combination of SSRI/SNRI and antiplatelet therapy, relative to aspirin alone, was associated with an increased risk of gastrointestinal bleeding, hemorrhagic stroke, or other bleeding. 13 An increased risk of gastrointestinal bleeding was recently associated with combined warfarin and SSRI/ SNRI, but the risk did not seem to be related to the SSRI/ SNRI affinity rate.
17
The strength of our work lies in its population-based design. We were able to collect data on all patients who had suffered a WA-PICH while living within a defined geographic area. In our population the proportion of WA- PICHs was 18.5%, a rather high number indicating that all warfarin users were found. An additional strength was the collection and double-checking of the data on SSRI/ SNRI. Because of this method, we could make reliable conclusions even with the retrospective study design. Nonetheless, the study has many limitations. First, aspirin use could not be double-checked from the national register; however, we still have the hospital data, and over-thecounter sales could be suspected to have only a minimal impact. Second, the patient population was too small to reveal any significant differences between various serotonin-modulating substances, and we had to combine the SSRI and SNRI data in these analyses. Therefore, no detailed conclusions can be drawn. Third, we had 3 subjects who had been taking aspirin, warfarin, and SSRI/SNRI simultaneously, and that could have influenced our results. Fourth, bleeding tendency beyond routine tests was not used to prove impaired platelet function in patients taking an SSRI/SNRI. Finally, only a few subjects had had a second head CT scan to verify rapid enlargement of the hematoma, so that the status of this condition as a cause of an increased case fatality rate remains speculative.
Conclusions
In summary, we observed that the use of serotoninmodulating antidepressants together with warfarin, compared with warfarin alone, seems to be associated with increased case fatality among patients with PICH. According to this population-based study, the use of serotonin-modulating antidepressants in patients already taking warfarin should be carefully considered or even avoided, until its safety is proven by larger population studies. An increased bleeding risk should be taken into account if surgical hematoma evacuation is planned in these patients.
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